IGC Pharma Q4 2024 GAAP EPS $(0.04), Sales $295.000K Beat $193.000K Estimate
IGC Pharma Q4 2024 GAAP EPS $(0.04), Sales $295.000K Beat $193.000K Estimate
igc pharma 2024年第四季度GAAP每股收益为$(0.04)，销售额为295,000美元，超过了193,000美元的估计
IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.04) per share. The company reported quarterly sales of $295.000 thousand which beat the analyst consensus estimate of $193.000 thousand by 52.85 percent. This is a 77.71 percent increase over sales of $166.000 thousand the same period last year.
IGC Pharma（美国证券交易所股票代码：IGC）公布的季度亏损为每股0.04美元。该公司公布的季度销售额为29.5万美元，比分析师普遍预期的19.3万美元高出52.85％。这比去年同期的16.6万美元的销售额增长了77.71％。